Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and uncertainty about a process largely held behind closed doors, just as another round of talks begin in the coming weeks under a new administration.

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, 46brooklyn Research, an Ohio non-profit focused on U.S. drug pricing data, said in a report on Thursday.

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit, enrollees are responsible for 25 percent of their dr